|
| 37069330 | Radiotheranostics in advanced prostate cancer: Current and future directions. | Prostate Cancer Prostatic Dis | 2024 |
| 37482523 | Case Series of Men with the Germline APC I1307K variant and Treatment-Emergent Neuroendocrine Prostate Cancer. | Clin Genitourin Cancer | 2024 |
| 37980367 | Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). | Br J Cancer | 2024 |
| 36347717 | B7-H3 and Prostate Cancer: New Therapeutic Dance Partners. | Eur Urol | 2023 |
| 37806842 | Clinical and Functional Analyses of an African-ancestry Gain-of-function HOXB13 Variant Implicated in Aggressive Prostate Cancer. | Eur Urol Oncol | 2023 |
| 38072760 | Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. | Eur Urol Oncol | 2023 |
| 37677121 | Opposing Roles of <i>SPOP</i> Mutations in Human Prostate and Endometrial Cancers. | JCO Precis Oncol | 2023 |
| 37971875 | MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression. | JCI Insight | 2023 |
| 37769224 | Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response. | JCO Precis Oncol | 2023 |
| 37969378 | Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta? | Transl Cancer Res | 2023 |
| 37126020 | Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes. | Clin Cancer Res | 2023 |
| 36952642 | Combining Poly(ADP)-Ribose Polymerase Inhibitors With Abiraterone in Castration-Resistant Prostate Cancer: Is Biomarker Testing Necessary? | J Clin Oncol | 2023 |
| 37290800 | SNMMI Consensus Statement on Patient Selection and Appropriate Use of <sup>177</sup>Lu-PSMA-617 Radionuclide Therapy. | J Nucl Med | 2023 |
| 37087376 | PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. | Eur Urol | 2023 |
| 37059746 | ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems. | Commun Biol | 2023 |
| 37058234 | Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. | Clin Cancer Res | 2023 |
| 37290035 | Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. | J Clin Oncol | 2023 |
| 37185436 | Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond. | Curr Oncol | 2023 |
| 37012549 | Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. | Nat Med | 2023 |
| 37112881 | Infectivity-Enhanced, Conditionally Replicative Adenovirus for COX-2-Expressing Castration-Resistant Prostate Cancer. | Viruses | 2023 |
| 37337669 | Clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case-control study. | Prostate | 2023 |
| 37140166 | Familial Clonal Hematopoiesis in a Long Telomere Syndrome. | N Engl J Med | 2023 |
| 36972661 | Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. | Eur J Cancer | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 36999911 | Impact of piflufolastat F-18 PSMA PET imaging on clinical decision-making in prostate cancer across disease states: A retrospective review. | Prostate | 2023 |
| 37477913 | Unique Spectrum of Activating BRAF Alterations in Prostate Cancer. | Clin Cancer Res | 2023 |
| 37196219 | MLH1 Loss in Primary Prostate Cancer. | JCO Precis Oncol | 2023 |
| 36996380 | Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). | J Clin Oncol | 2023 |
| 37027449 | Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer. | Oncologist | 2023 |
| 36959766 | Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer. | Prostate | 2023 |
| 36857796 | Role of bromodomain and extraterminal (BET) proteins in prostate cancer. | Expert Opin Investig Drugs | 2023 |
| 36653039 | Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline <i>CHEK2</i> mutation. | BMJ Case Rep | 2023 |
| 36708787 | WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer. | Int J Radiat Oncol Biol Phys | 2023 |
| 36897758 | PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. | Clin Cancer Res | 2023 |
| 36865273 | MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression. | bioRxiv | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 36564933 | A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide. | Prostate | 2023 |
| 36628897 | Updated analyses for RESTORE cohort C: A trial of bipolar androgen therapy for patients with newly castration-resistant prostate cancer. | Eur J Cancer | 2023 |
| 36367998 | Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. | J Clin Oncol | 2023 |
| 36382533 | Differential responses to taxanes and PARP inhibitors in ATM-Â versus BRCA2-mutated metastatic castrate-resistant prostate cancer. | Prostate | 2023 |
| 34257408 | Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2022 |
| 35772050 | PARP Inhibitor Insensitivity to <i>BRCA1/2</i> Monoallelic Mutations in Microsatellite Instability-High Cancers. | JCO Precis Oncol | 2022 |
| 35677016 | Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss. | Eur Urol Open Sci | 2022 |
| 35820087 | Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. | JCO Precis Oncol | 2022 |
| 35594523 | The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management. | Expert Rev Anticancer Ther | 2022 |
| 35416959 | A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent. | Clin Cancer Res | 2022 |
| 35657154 | Genetics and genomics of prostate cancer and therapeutic implications. | Prostate | 2022 |
| 35357024 | Bipolar androgen therapy (BAT): A patient's guide. | Prostate | 2022 |
| 36557020 | <i>BRCA1/2</i> Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents. | Medicina (Kaunas) | 2022 |
| 36001857 | Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. | J Clin Oncol | 2022 |